This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) ##STR00001##

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) ##STR00001##

The present invention provides compounds of Formula (I): useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

##STR00001##

The present invention provides compounds of Formula (I): useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

##STR00001##

The present invention provides novel compounds having the general formula (I) wherein R.sup.1 to R.sup.6, and m are as described herein, compositions including the compounds and methods of using the compounds.

##STR00001##

The present invention relates to use of a chelating compound for chromatographic separation of rare earth elements, actinides, and/or s-, p- and d-block metals, and to a method of chromatographic separation of chelates of rare earth elements, actinides and/or s-, p- and d-block metals from a mixture of at least two metal ions. The method is characterized in that it comprises the following steps: (a) providing a mixture of at least two different metal ions chosen from rare earth metal ions, actinide ions and/or s-, p- and d-block metal ions, (b) contacting metal ions comprised in said mixture to with at least one compound of general formula (I) as defined in any one of the preceding claims to form chelates; (c) subjecting the chelates from step (b) to chromatographic separation, wherein optionally at least one separated metal chelate obtained in step (c) can be subjected to at least one further chromatographic separation in order to increase the purity of the at least one separated metal chelate; and, optionally, (d) obtaining the metal from the at least one separated metal chelate.

The present invention relates to use of a chelating compound for chromatographic separation of rare earth elements, actinides, and/or s-, p- and d-block metals, and to a method of chromatographic separation of chelates of rare earth elements, actinides and/or s-, p- and d-block metals from a mixture of at least two metal ions. The method is characterized in that it comprises the following steps: (a) providing a mixture of at least two different metal ions chosen from rare earth metal ions, actinide ions and/or s-, p- and d-block metal ions, (b) contacting metal ions comprised in said mixture to with at least one compound of general formula (I) as defined in any one of the preceding claims to form chelates; (c) subjecting the chelates from step (b) to chromatographic separation, wherein optionally at least one separated metal chelate obtained in step (c) can be subjected to at least one further chromatographic separation in order to increase the purity of the at least one separated metal chelate; and, optionally, (d) obtaining the metal from the at least one separated metal chelate.

The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.

Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.